trial · primary record
Osimertinib
Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 367 |
| Primary completion | 2027-03-31 |
| Primary endpoint | Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis Set |
| Registry ID | NCT03778229 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:02.546Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03778229
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Osimertinib · compound